Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Mingozzi

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2009
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transductionJonathan D Finn, Daniel Hui, Harre D Downey, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2009
Host and vector-dependent effects on the risk of germline transmission of AAV vectorsPatricia Favaro, Harre D Downey, J Shangzhen Zhou, et al.
Plos One|June 25, 2015
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid ArthritisCaroline J Aalbers, Lisette Bevaart, Scott Loiler, et al.
Human Gene Therapy|August 21, 2004
Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vectorYi-Lin Liu, Federico Mingozzi, Sol M Rodriguéz-Colôn, et al.
Human Gene Therapy|November 11, 2014
Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockadeSang-oh Han, Songtao Li, Elizabeth D Brooks, et al.
Plos One|July 12, 2013
IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expressionIrene Gil-Fariña, Marianna Di Scala, Lucia Vanrell, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 17, 2023
Analysis of Adeno-Associated Virus Serotype 8 (AAV8)-antibody complexes using epitope mapping by molecular imprinting leads to the identification of Fab peptides that potentially evade AAV8 neutralisationElena Piletska, Philippe Veron, Bérangère Bertin, et al.
The Journal of Clinical Investigation|October 24, 2018
Exposure to wild-type AAV drives distinct capsid immunity profiles in humansKlaudia Kuranda, Priscilla Jean-Alphonse, Christian Leborgne, et al.
Molecular Therapy. Methods & Clinical Development|October 26, 2019
Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in MuscleJérôme Poupiot, Helena Costa Verdera, Romain Hardet, et al.
Ebiomedicine|November 24, 2020
Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosidesFerran Vila-Julià, Raquel Cabrera-Pérez, Yolanda Cámara, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2009
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transductionJonathan D Finn, Daniel Hui, Harre D Downey, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2009
Host and vector-dependent effects on the risk of germline transmission of AAV vectorsPatricia Favaro, Harre D Downey, J Shangzhen Zhou, et al.
Plos One|June 25, 2015
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid ArthritisCaroline J Aalbers, Lisette Bevaart, Scott Loiler, et al.
Human Gene Therapy|August 21, 2004
Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vectorYi-Lin Liu, Federico Mingozzi, Sol M Rodriguéz-Colôn, et al.
Human Gene Therapy|November 11, 2014
Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockadeSang-oh Han, Songtao Li, Elizabeth D Brooks, et al.
Plos One|July 12, 2013
IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expressionIrene Gil-Fariña, Marianna Di Scala, Lucia Vanrell, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 17, 2023
Analysis of Adeno-Associated Virus Serotype 8 (AAV8)-antibody complexes using epitope mapping by molecular imprinting leads to the identification of Fab peptides that potentially evade AAV8 neutralisationElena Piletska, Philippe Veron, Bérangère Bertin, et al.
The Journal of Clinical Investigation|October 24, 2018
Exposure to wild-type AAV drives distinct capsid immunity profiles in humansKlaudia Kuranda, Priscilla Jean-Alphonse, Christian Leborgne, et al.
Molecular Therapy. Methods & Clinical Development|October 26, 2019
Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in MuscleJérôme Poupiot, Helena Costa Verdera, Romain Hardet, et al.
Ebiomedicine|November 24, 2020
Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosidesFerran Vila-Julià, Raquel Cabrera-Pérez, Yolanda Cámara, et al.
Pageof 14